Tags

Type your tag names separated by a space and hit enter

Effectiveness and Safety of Apixaban and Rivaroxaban for Acute Venous Thromboembolism Therapy in Patients with Extremes in Body Weight (ClinicalTrials.gov: NCT03504007).
Eur J Haematol. 2020 Jun 17 [Online ahead of print]EJ

Abstract

OBJECTIVES

To investigate the association of extremes in body weight EBW and outcomes in patients with acute venous thromboembolism (VTE), recurrent VTE, major bleeding, and clinically relevant non-major bleeding were compared between patients with body weight <60 kg, 60-120 kg, and >120 kg.

METHODS

Consecutive patients enrolled in the Mayo Clinic VTE Registry (03/28/2013-8/31/2019) with acute VTE were followed prospectively. Patient status was assessed in person, by mailing a written questionnaire, or by a scripted phone interview.

RESULTS

Amongst 2577 patients with the weight ranging from 27.0 kg to 263.2 kg, 2123 (82%) had a bodyweight between 60 - 120 kg, 223 (8.7%) bodyweight <60 kg, and 230 (8.9%) bodyweight >120 kg. Patients with bodyweight <60kg treated with DOACs had higher 3- and 6-month incidence of major bleeding compared to the bodyweight 60-120kg group (4.4% vs 1.1%, p=0.03, and 4.4% vs 1.4%, p=0.05, respectively). Patients with bodyweight >120kg and cancer on rivaroxaban had higher VTE recurrence compared to bodyweight 60-120kg group (p=0.01).

CONCLUSIONS

Treatment of acute VTE is associated with a higher incidence of bleeding in patients with bodyweight <60kg. A higher VTE recurrence rate occurred only in cancer patients with bodyweight >120kg on rivaroxaban.

Authors+Show Affiliations

Gonda Vascular Center, Thrombophilia Clinic, Division of Cardiovascular Diseases, Mayo Clinic Rochester, MN, United States.Gonda Vascular Center, Thrombophilia Clinic, Division of Cardiovascular Diseases, Mayo Clinic Rochester, MN, United States.Gonda Vascular Center, Thrombophilia Clinic, Division of Cardiovascular Diseases, Mayo Clinic Rochester, MN, United States.Gonda Vascular Center, Thrombophilia Clinic, Division of Cardiovascular Diseases, Mayo Clinic Rochester, MN, United States.Gonda Vascular Center, Thrombophilia Clinic, Division of Cardiovascular Diseases, Mayo Clinic Rochester, MN, United States.Gonda Vascular Center, Thrombophilia Clinic, Division of Cardiovascular Diseases, Mayo Clinic Rochester, MN, United States.Gonda Vascular Center, Thrombophilia Clinic, Division of Cardiovascular Diseases, Mayo Clinic Rochester, MN, United States.Gonda Vascular Center, Thrombophilia Clinic, Division of Cardiovascular Diseases, Mayo Clinic Rochester, MN, United States.Gonda Vascular Center, Thrombophilia Clinic, Division of Cardiovascular Diseases, Mayo Clinic Rochester, MN, United States.Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, United States.Gonda Vascular Center, Thrombophilia Clinic, Division of Cardiovascular Diseases, Mayo Clinic Rochester, MN, United States.Gonda Vascular Center, Thrombophilia Clinic, Division of Cardiovascular Diseases, Mayo Clinic Rochester, MN, United States.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32557773

Citation

Wysokinski, Waldemar E., et al. "Effectiveness and Safety of Apixaban and Rivaroxaban for Acute Venous Thromboembolism Therapy in Patients With Extremes in Body Weight (ClinicalTrials.gov: NCT03504007)." European Journal of Haematology, 2020.
Wysokinski WE, Froehling DA, Houghton DE, et al. Effectiveness and Safety of Apixaban and Rivaroxaban for Acute Venous Thromboembolism Therapy in Patients with Extremes in Body Weight (ClinicalTrials.gov: NCT03504007). Eur J Haematol. 2020.
Wysokinski, W. E., Froehling, D. A., Houghton, D. E., McBane, R. D., Vlazny, D. T., Bott-Kitslaar, D. M., Kuczmik, W., Sutkowska, K., Bator, K., Hodge, D. O., Peterson, L. G., & Casanegra, A. I. (2020). Effectiveness and Safety of Apixaban and Rivaroxaban for Acute Venous Thromboembolism Therapy in Patients with Extremes in Body Weight (ClinicalTrials.gov: NCT03504007). European Journal of Haematology. https://doi.org/10.1111/ejh.13471
Wysokinski WE, et al. Effectiveness and Safety of Apixaban and Rivaroxaban for Acute Venous Thromboembolism Therapy in Patients With Extremes in Body Weight (ClinicalTrials.gov: NCT03504007). Eur J Haematol. 2020 Jun 17; PubMed PMID: 32557773.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness and Safety of Apixaban and Rivaroxaban for Acute Venous Thromboembolism Therapy in Patients with Extremes in Body Weight (ClinicalTrials.gov: NCT03504007). AU - Wysokinski,Waldemar E, AU - Froehling,David A, AU - Houghton,Damon E, AU - McBane,Robert D, AU - Vlazny,Danielle T, AU - Bott-Kitslaar,Dalene M, AU - Kuczmik,Wiktoria, AU - Sutkowska,Karolina, AU - Bator,Kaja, AU - Hodge,David O, AU - Peterson,Lisa G, AU - Casanegra,Ana I, Y1 - 2020/06/17/ PY - 2020/6/20/entrez KW - apixaban KW - bodyweight extremes KW - direct oral anticoagulants KW - malignancy KW - rivaroxaban KW - venous thromboembolism JF - European journal of haematology JO - Eur. J. Haematol. N2 - OBJECTIVES: To investigate the association of extremes in body weight EBW and outcomes in patients with acute venous thromboembolism (VTE), recurrent VTE, major bleeding, and clinically relevant non-major bleeding were compared between patients with body weight <60 kg, 60-120 kg, and >120 kg. METHODS: Consecutive patients enrolled in the Mayo Clinic VTE Registry (03/28/2013-8/31/2019) with acute VTE were followed prospectively. Patient status was assessed in person, by mailing a written questionnaire, or by a scripted phone interview. RESULTS: Amongst 2577 patients with the weight ranging from 27.0 kg to 263.2 kg, 2123 (82%) had a bodyweight between 60 - 120 kg, 223 (8.7%) bodyweight <60 kg, and 230 (8.9%) bodyweight >120 kg. Patients with bodyweight <60kg treated with DOACs had higher 3- and 6-month incidence of major bleeding compared to the bodyweight 60-120kg group (4.4% vs 1.1%, p=0.03, and 4.4% vs 1.4%, p=0.05, respectively). Patients with bodyweight >120kg and cancer on rivaroxaban had higher VTE recurrence compared to bodyweight 60-120kg group (p=0.01). CONCLUSIONS: Treatment of acute VTE is associated with a higher incidence of bleeding in patients with bodyweight <60kg. A higher VTE recurrence rate occurred only in cancer patients with bodyweight >120kg on rivaroxaban. SN - 1600-0609 UR - https://www.unboundmedicine.com/medline/citation/32557773/Effectiveness_and_Safety_of_Apixaban_and_Rivaroxaban_for_Acute_Venous_Thromboembolism_Therapy_in_Patients_with_Extremes_in_Body_Weight_(ClinicalTrials.gov:_NCT03504007) L2 - https://doi.org/10.1111/ejh.13471 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.